跳至主要内容
临床试验/NL-OMON49111
NL-OMON49111撤回2 期

TriGUARD 3 TransCranial Doppler (TCD) Ultrasound Study: A prospective, randomized, real-time evaluation of blood filtration with the TriGUARD 3 Embolic Protection Device Using TCD During Transcatheter Aortic Valve Implantation (TAVI). - Triguard 3 - TCD study

Keystone Heart0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
撤回
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. The patient must be * 18 years of age.
  • 2. The patient meets indications for TAVI procedure.
  • 3. The patient has been informed of the nature of the study, agrees to its
  • provisions and has been provided written informed consent, approved by the
  • appropriate Medical Ethics Committee (EC)
  • 4. The patient is willing to comply with specified follow-up evaluations.

排除标准

  • 1.Patients undergoing TAVI via the trans-axillary, transapical, subclavian, or
  • direct aortic route
  • 2 Patients with impaired renal function (estimated Glomerular Filtration Rate
  • [eGFR] <30, calculated from serum creatinine by the Cockcroft-Gault formula).
  • 3.Patients with a history of a stroke or transient ischemic attack (TIA) within
  • the prior 6 months.
  • 4.Patients with severe peripheral arterial disease that precludes the delivery
  • sheath vascular access.
  • 5.Patients who have a planned treatment with any other investigational device
  • or procedure during the study period.
  • 6.Patients planned to undergo any other cardiac surgical or interventional
  • procedure during the TAVI procedure (e.g., concurrent coronary
  • revascularization or within 10 days prior to the TAVI procedure. NOTE:
  • Diagnostic cardiac catheterization is permitted within 10 days prior to the
  • TAVI procedure.
  • 7 Patients who have closed temporal window(s).
  • 8. Patients with scheduled valve-in-valve procedure

研究者

发起方
Keystone Heart

相似试验